Zhou, Z, Nath, R, Cerny, J, Wang, HL, Zhang, MJ
, Abdel-Azim, H, Agrawal, V, Ahmed, G, Al-Homsi, AS, Aljurf, M, Alkhateeb, HB, Assal, A, Bacher, U, Bajel, A, Bashir, Q, Battiwalla, M, Bhatt, VR, Byrne, M, Cahn, JY, Cairo, M, Choe, H, Copelan, E, Cutler, C, Damlaj, MB, Defilipp, Z, Lima, MD, Diaz, MA, Farhadfar, N, Foran, J, Freytes, CEO, Gerds, AT, Gergis, U, Grunwald, MR, Gul, Z, Hamadani, M, Hashmi, S, Hertzberg, M, Hildebrandt, GC, Hossain, N, Inamoto, Y, Isola, L, Jain, T, Kamble, RT, Khan, MW, Kharfan-Dabaja, MA, Kebriaei, P, Kekre, N, Khera, N, Lazarus, HM, Liesveld, JL, Litzow, M, Liu, H, Marks, DI, Martino, R, Mathews, V, Mishra, A, Murthy, HS, Nagler, A, Nakamura, R, Nathan, S, Nishihori, T, Olin, R, Olsson, RF, Palmisiano, N, Patel, SS, Patnaik, MM, Pawarode, A, Perales, MA, Politikos, I, Popat, U, Rizzieri, D, Sandmaier, BM, Savani, BN, Seo, S, Shah, NN, Uy, GL, Arcel, DVA, Verdonck, LF, Waller, EK, Wang, Y, Weisdorf, D, Wirk, B, Wong, E, Yared, JA & Saber, W 2020, '
Reduced intensity conditioning for acute myeloid leukemia using melphalan-vs busulfan-based regimens: A CIBMTR report',
Blood Advances, vol. 4, no. 13, pp. 3180-3190.
https://doi.org/10.1182/bloodadvances.2019001266